APUS
AMEXApimeds Pharmaceuticals US Inc.
Apimeds Pharmaceuticals US Inc. (APUS) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 7 wire items for APUS, including 3 press releases and news items, 3 insider trades and 1 SEC filing. The most recent was published Nov 9, 2026.
APUS rankings
Financial highlights
Full financials- Net income, TTM
- -$58.17M
- Free cash flow, TTM
- -$13.33M
- Cash
- $278.4K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks23-44%
2026-05-172026-11-08
Mix1890d
- Other8(44%)
- SEC Filings7(39%)
- Insider3(17%)
Activity · 52 weeks5341 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRMindWave Innovations Inc. USA and Skalup Capital Singapore Form Bermuda Insurance Joint Venture, Pursue Insurance License with Bermuda Monetary AuthorityJoint venture pairs MindWave’s blockchain infrastructure and digital-asset-backed capital, in the form of staking, with Skalup’s insurance expertise to build reinsurance capacity in one of the world’s leading insurance markets MATAWAN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- via IBN — MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has entered into a Shareholders’ and Joint Venture Agreement with Singapore-based Skalup Capital Pte Ltd ("Skalup") to establish an insurance and technology business in Bermuda under the working brand Monaco Insurance, subject to final regulatory approval. The agreement brings tog
- INSIDERSEC Form 3 filed by new insider Chae Sungjoon3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- PRIBN Announces CryptoCurrencyWire Audio Production Featuring Dr. Vin Menon, CEO of MindWave Innovations Inc.AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest CryptoCurrencyWire Audio Production as part of its sustained effort to provide specialized content distribution via widespread syndication channels. CryptoCurrencyWire’s latest audio production features Dr. Vin Menon, CEO of MindWave Innovations Inc. (NYSE:APUS), a digital asset and technology company providing institutional-grade treasury infrastructure for the digital asset economy. To begin the interview, Menon discussed MindWave's development of MindChain, an inst
- INSIDERSEC Form 3 filed by new insider Sherb Eric Michael3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- INSIDERSEC Form 3 filed by new insider Menon Vin3 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
- PRNILA Token to Begin Trading on Pionex, Opening Access to Eligible Users WorldwideMATAWAN, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), today announced that NILA, the native token of the MindChain network, will be available on Pionex (https://www.pionex.com/en/), with trading scheduled to begin on Wednesday, Oct. 14, 2026, at 6 a.m. Eastern Time. The listing gives eligible users in the jurisdictions served by Pionex a direct, simple route to NILA on an established global exchange, ahead of NILA's planned move to its own network, MindChain. About Pionex Pionex is a global cryptocurrency exchange known for its built-in automated trading bots, incl
- SECSEC Form 8-K filed by Apimeds Pharmaceuticals US Inc.8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- PRMindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American DisclosureMATAWAN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), signed three agreements between Sept. 24 and Oct. 4, 2026, to build and operate dedicated blockchain networks for clients in climate finance, sports media and insurance, all running on MindChain. The three agreements follow the same model. MindWave builds and runs a dedicated network for each client on MindChain and is compensated through contracted fees or equity, together with an allocation equal to 20% of the credits or tokens issued on that client's network. Two of the three clients are U.S. companies, expandi
- PRMindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance NetworkMATAWAN, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. ("BlockAssure") to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure's insurance and reinsurance operations on-chain. For MindWave, this is an important expansion of its U.S. business. It takes the company's technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client. "BlockAssure chose us to build AssureChain, and
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- PRMindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & MediaMATAWAN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings, Inc. (FLZH) to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. Under the agreement, MindWave will deploy a dedicated subnet for FlashChain on MindChain's Layer-2 infrastructure, operate the validator nodes that run it, and issue FLZH the cryptographic keys and secure connections it needs to access the network. FLZH will own
- PRMindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI CreditsMATAWAN, New Jersey, Sept. 24, 2026 (GLOBE NEWSWIRE) -- via IBN — MindWave Innovations Inc. ("MindWave"), a subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. ("AQUAE") to deploy its MindChain infrastructure as the foundation of AQUAEChain, a platform for insured ALCI Credits. Under the agreement, MindWave will design, develop, deploy and host AQUAEChain, and provide technical support once it is live. The platform will manage the full life of an ALCI Credit: issuance, verification, tracking, transfer and retirement. MindWave will earn contracted software development and technology s
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- PRIBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US, is developing institutional digital asset infrastructure connecting treasury, insurance, tokenized assets and blockchain ecosystems. Its platform combines insured custody, transparent reporting and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy. As p
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECSEC Form 10-Q filed by Apimeds Pharmaceuticals US Inc.10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- PRNILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency ExchangeMATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc." or the "Company"), today announced that its NILA token is now available to eligible users in the United States on Webot, a licensed U.S. cryptocurrency exchange. Starting today, eligible U.S. users may access NILA on a licensed American platform for the first time. For anyone new to NILA, this makes it simpler to get started. Eligible users may access the token through a U.S. exchange that operates under applicable licenses, ahead of NILA moving to its own network, M
- PRMindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in OctoberMATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc" or the "Company"), today announced MindChain, the world's first fully insured blockchain. MindChain is an insured, production-grade, EVM-compatible Layer 2 network that will go live in October 2026. It gives the MindWave ecosystem its own network, run by its own sequencer and validator set, while every transaction settles on Ethereum for final security. The Company also announced that the NILA token will be available to the U.S. market on Webot beginning Aug. 3,
- SECApimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECSEC Form 10-Q filed by Apimeds Pharmaceuticals US Inc.10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- SECSEC Form NT 10-Q filed by Apimeds Pharmaceuticals US Inc.NT 10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
- PRApimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox ProgramTrading Expected to Resume on NYSE American on Tuesday, May 5 Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement of Lōkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS' common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 20
APUS FAQ
8 questionsWhat is the latest news on APUS?
In the last 30 days Quantisnow tracked 7 wire items for APUS: 3 press releases and news items, 3 insider trades and 1 SEC filing. The most recent was published on November 9, 2026.Is APUS profitable?
No. Apimeds Pharmaceuticals US Inc. reported a net loss of $58.17M for the twelve months ended Jun 30, 2026.How much cash and debt does APUS have?
Apimeds Pharmaceuticals US Inc. reported $278.4K in cash and cash equivalents and $5.00M of debt on its most recent balance sheet in SEC filings.Where does APUS stock trade?
Apimeds Pharmaceuticals US Inc. (APUS) is listed on AMEX.What sector and industry is APUS in?
Apimeds Pharmaceuticals US Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Apimeds Pharmaceuticals US Inc. go public?
Apimeds Pharmaceuticals US Inc. (APUS) completed its IPO in 2025.What companies are similar to APUS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare APUS side-by-side with any of them on Quantisnow.How can I track APUS on Quantisnow?
Quantisnow aggregates Apimeds Pharmaceuticals US Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APUS to receive live email and push alerts on every new disclosure.